News

The Phase Ib trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of three months and 18

As part of the deal, Capricor has been granted an exclusive world-wide license, with the right to sublicense, IP related to exosomes originating from cardiosphere-derived cells (CDCs). The

The patent, which has terms that expire no earlier than 2031, covers the company’s unique formulation in conjunction with anti-obesity agents for the reduction of body weight in

The agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria, and etoricoxib is marketed under the brand name of Arcoxia in these markets. Grünenthal chief commercial officer

The agreement will allow the discovery and development of potential oral first-in-class compounds that inhibit Macrophage Migration Inhibitory Factor (MIF), a major regulatory cytokine that has been linked

The company announced the issuance of US Patent No. 8,701,658 entitled ‘Ventilation Circuit Adaptor and Proximal Aerosol Delivery System’ which provides coverage for our novel disposable aerosol airway

Used for years to treat allergic asthma, the drug has been tested for the treatment of chronic hives with overwhelmingly positive results. For those that suffer from chronic

The patent covers Can-Fite’s drug, CF102 in the treatment of the liver function following liver resection (surgery) by helping the liver to regenerate and repair itself. In preclinical

In 2013, BIO and ViS launched this initiative to improve the efficiency of clinical development for pediatric therapeutics. BIO and its member companies work with ViS to use